Activation of AKT kinases in cancer: Implications for therapeutic targeting

Advances in Cancer Research

Volumn 94, Issue 1 SUPPL., 2005, Pages 29-86

  Bellacosa, Alfonso ^a   Kumar, C Chandra ^b   Cristofano, Antonio Di ^a   Testa, Joseph Robert ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AP 25373; DNA TOPOISOMERASE INHIBITOR; EVEROLIMUS; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN TYROSINE KINASE; RAPAMYCIN; STAUROSPORINE; TACROLIMUS; TEMSIROLIMUS; TOPOTECAN; TUBERIN; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME METABOLISM; ENZYME STRUCTURE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; THYROID CARCINOMA; WESTERN BLOTTING;

ANIMALS; ENZYME ACTIVATION; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 23944526062     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(05)94002-5     Document Type: Review

References (246)

1. Ackler S., Ahmad S., Tobias C., Johnson M.D., and Glazer R.I. Delayed mammary gland involution in MMTV-AKT1 transgenic mice Oncogene 21 2002 198 206
2. Ahmed N.N., Franke T.F., Bellacosa A., Datta K., Gonzalez-Portal M.E., Taguchi T., Testa J.R., and Tsichlis P.N. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential Oncogene 8 1993 1957 1963
3. Alessi D.R., and Cohen P. Mechanism of activation and function of protein kinase B Curr. Opin. Genet. Dev. 8 1998 55 62
4. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., and Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1 EMBO J. 15 1996 6541 6551
5. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., and Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha Curr. Biol. 7 1997 261 269
6. Alkan S., and Izban K.F. Immunohistochemical localization of phosphorylated AKT in multiple myeloma Blood 99 2002 2278 2279
7. Altomare D.A., Tanno S., De Rienzo A., Klein-Szanto A., Skele K.L., Hoffman J.P., and Testa J.R. Frequent activation of AKT2 kinase in human pancreatic carcinomas J. Cell. Biochem. 87 2003 470 476
8. Altomare D.A., Wang H.Q., Skele K.L., Rienzo A.D., Klein-Szanto A.J., Godwin A.K., and Testa J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 23 2004 5853 5857
9. Aoki K., Tamai Y., Horiike S., Oshima M., and Taketo M.M. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice Nat. Genet. 35 2003 323 330
10. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., Danino M., Karlan B.Y., and Slamon D.J. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells Cancer Res. 63 2003 196 206
11. Arranz E., Robledo M., Martinez B., Gallego J., Roman A., Rivas C., and Benitez J. Incidence of homogeneously staining regions in non-Hodgkin lymphomas Cancer Genet. Cytogenet. 87 1996 1 3
12. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., Park Y., Liou S.H., Marshall B., Boni J.P., Dukart G., and Sherman M.L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J. Clin. Oncol. 22 2004 909 918
13. Avdulov S., Li S., Michalek V., Burrichter D., Peterson M., Perlman D.M., Manivel J.C., Sonenberg N., Yee D., Bitterman P.B., and Polunovsky V.A. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells Cancer Cell 5 2004 553 563
14. Backman S.A., Stambolic V., Suzuki A., Haight J., Elia A., Pretorius J., Tsao M.S., Shannon P., Bolon B., Ivy G.O., and Mak T.W. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease Nat. Genet. 29 2001 396 403
15. Backman S.A., Ghazarian D., So K., Sanchez O., Wagner K.U., Hennighausen L., Suzuki A., Tsao M.S., Chapman W.B., Stambolic V., and Mak T.W. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten Proc. Natl. Acad. Sci. USA 101 2004 1725 1730
16. Bacus S.S., Altomare D.A., Lyass L., Chin D.M., Farrell M.P., Gurova K., Gudkov A., and Testa J.R. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival Oncogene 21 2002 3532 3540
17. Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P., Currie R., Downes C.P., and Alessi D.R. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 Curr. Biol. 9 1999 393 404
18. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., Unger M., and Testa J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis 25 2004 2053 2059
19. Bellacosa A. Genetic hits and mutation rate in colorectal tumorigenesis: Versatility of Knudson's theory and implications for cancer prevention Genes Chromosomes Cancer 38 2003 382 388
20. Bellacosa A., Testa J.R., Staal S.P., and Tsichlis P.N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region Science 254 1991 274 277
21. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., and Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int. J. Cancer 64 1995 280 285
22. Bellacosa A., Chan T.O., Ahmed N.N., Datta K., Malstrom S., Stokoe D., McCormick F., Feng J., and Tsichlis P. Akt activation by growth factors is a multiple-step process: The role of the PH domain Oncogene 17 1998 313 325
23. Bellacosa A., Testa J.R., Moore R., and Larue L. A portrait of AKT kinases: Human cancer and animal models depict a family with strong individualities Cancer Biol. Ther. 3 2004 267 275
24. Biondi R.M., Komander D., Thomas C.C., Lizcano J.M., Deak M., Alessi D.R., and van Aalten D.M. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site EMBO J. 21 2002 4219 4228
25. Bjornsti M.A., and Houghton P.J. Lost in translation: Dysregulation of cap-dependent translation and cancer Cancer Cell 5 2004 519 523
26. Blackhall F.H., Pintilie M., Michael M., Leighl N., Feld R., Tsao M.S., and Shepherd F.A. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer Clin. Cancer Res. 9 2003 2241 2247
27. Boudeau J., Sapkota G., and Alessi D.R. LKB1, a protein kinase regulating cell proliferation and polarity FEBS Lett. 546 2003 159 165
28. Boulay A., Zumstein-Mecker S., Stephan C., Beuvink I., Zilbermann F., Haller R., Tobler S., Heusser C., O'Reilly T., Stolz B., Marti A., Thomas G., and Lane H.A. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells Cancer Res. 64 2004 252 261
29. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts Trends Biochem. Sci. 29 2004 233 242
30. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res. 61 2001 3986 3997
31. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 1999 857 868
32. Byun D.S., Cho K., Ryu B.K., Lee M.G., Park J.I., Chae K.S., Kim H.J., and Chi S.G. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma Int. J. Cancer 104 2003 318 327
33. Cantley L.C. The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
34. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc. Natl. Acad. Sci. USA 96 1999 4240 4245
35. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control Trends Biochem. Sci. 29 2004 18 24
36. Chakravarti A., Zhai G., Suzuki Y., Sarkesh S., Black P.M., Muzikansky A., and Loeffler J.S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas J. Clin. Oncol. 22 2004 1926 1933
37. Chan T.O., and Tsichlis P.N. PDK2: A complex tail in one Akt Sci STKE 2001 2001 PE1
38. Chan T.O., Rittenhouse S.E., and Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide- dependent phosphorylation Annu. Rev. Biochem. 68 1999 965 1014
39. Chang H.W., Aoki M., Fruman D., Auger K.R., Bellacosa A., Tsichlis P.N., Cantley L.C., Roberts T.M., and Vogt P.K. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase Science 276 1997 1848 1850
40. Chaudhary L.R., and Hruska K.A. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells J. Cell. Biochem. 89 2003 1 5
41. Chen W.S., Xu P.Z., Gottlob K., Chen M.L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., Kadowaki T., Hay N., Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B. 3rd, Kaestner K.H., Bartolomei M.S., Shulman G.I., and Birnbaum M.J. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Genes Dev. 15 2001 2203 2208
42. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., and Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas Proc. Natl. Acad. Sci. USA 89 1992 9267 9271
43. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc. Natl. Acad. Sci. USA 93 1996 3636 3641
44. Cheng J.Q., Altomare D.A., Klein M.A., Lee W.-C., Kruh G.D., Lissy N.A., and Testa J.R. Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis Oncogene 14 1997 2793 2801
45. Cheong J.W., Eom J.I., Maeng H.Y., Lee S.T., Hahn J.S., Ko Y.W., and Min Y.H. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome Br. J. Haematol. 122 2003 454 456
46. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B., Kaestner K.H., Bartolomei M.S., Shulman G.I., and Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science 292 2001 1728 1731
47. Chun K.H., Kosmeder J.W., Sun S.H., Pezzuto J.M., Lotan R., Hong W.K., and Lee H.Y. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells J. Natl. Cancer Inst. 95 2003 291 302
48. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, Trastuzumab, or Tamoxifen in breast cancer cells Mol. Cancer Ther. 1 2002 707 717
49. Coffer P.J., and Woodgett J.R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families Eur. J. Biochem. 201 1991 475 481
50. Coffer P.J., Jin J., and Woodgett J.R. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation Biochem. J. 335 1998 1 13
51. Creagh E.M., and Martin S.J. Caspases: Cellular demolition experts Biochem. Soc. Trans. 29 2001 696 702
52. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 378 1995 785 789
53. Dancey J.E. Clinical development of mammalian target of rapamycin inhibitors Hematol. Oncol. Clin. North Am. 5 2002 1101 1114
54. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: A play in three Akts Genes Dev. 13 1999 2905 2927
55. Deprez J., Vertommen D., Alessi D.R., Hue L., and Rider M.H. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades J. Biol. Chem. 272 1997 17269 17275
56. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression Cell 100 2000 387 390
57. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression Nat. Genet. 19 1998 348 355
58. Di Cristofano A., Kotsi P., Peng Y.F., Cordon-Cardo C., Elkon K.B., and Pandolfi P.P. Impaired Fas response and autoimmunity in Pten+/- mice Science 285 1999 2122 2125
59. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization Genes Dev. 12 1998 3499 3511
60. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation Nature 399 1999 601 605
61. Djordjevic S., and Driscoll P.C. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases Trends Biochem. Sci. 8 2002 426 432
62. Douros J., and Suffness M. New antitumor substances of natural origin Cancer Treat. Rev. 8 1981 63 87
63. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt Curr. Opin. Cell Biol. 10 1998 262 267
64. Du K., Herzig S., Kulkarni R.N., and Montminy M. TRB3: A tribbles homolog that inhibits Akt/PKB activation by insulin in liver Science 300 2003 1574 1577
65. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., and Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt Science 275 1997 661 665
66. Duensing A., Medeiros F., McConarty B., Joseph N.E., Panigrahy D., Singer S., Fletcher C.D., Demetri G.D., and Fletcher J.A. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) Oncogene 23 2004 3999 4006
67. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., and Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells Cancer Res. 64 2004 3892 3899
68. Eng C. PTEN: One gene, many syndromes Hum. Mutat. 22 2003 183 198
69. Feng J., Park J., Cron P., Hess D., and Hemmings B.A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase J. Biol. Chem. 279 2004 41189 41196
70. Flynn P., Wongdagger M., Zavar M., Dean N.M., and Stokoe D. Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival Curr. Biol. 10 2000 1439 1442
71. Franke T.F., Kaplan D.R., and Cantley L.C. PI3K: Downstream AKTion blocks apoptosis Cell 88 1997 435 437
72. Franke T.F., Hornik C.P., Segev L., Shostak G.A., and Sugimoto C. PI3K/Akt and apoptosis: Size matters Oncogene 22 2003 8983 8998
73. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., and Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt Nature 399 1999 597 601
74. George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S., Wilson J.C., Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L., Dunger D.B., Barford D., Umpleby A.M., Wareham N.J., Davies H.A., Schafer A.J., Stoffel M., O'Rahilly S., and Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2 Science 304 2004 1325 1328
75. Gingras A.C., and Sonenberg N. Adenovirus infection inactivates the translational inhibitors 4E-BP1 and 4E-BP2 Virology 237 1997 182 186
76. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase Genes Dev. 15 2001 1406 1418
77. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., and Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 J. Biol. Chem. 275 2000 5600 5605
78. Grille S.J., Bellacosa A., Upson J., Klein-Szanto A.J., van Roy F., Lee-Kwon W., Donowitz M., Tsichlis P.N., and Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines Cancer Res. 63 2003 2172 2178
79. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., Kornblum H.I., Liu X., and Wu H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo Science 294 2001 2186 2189
80. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target Biochim. Biophys. Acta 1697 2004 3 16
81. Hanahan D., and Weinberg R.A. The hallmarks of cancer Cell 100 2000 57 70
82. Hashimoto K., Mori N., Tamesa T., Okada T., Kawauchi S., Oga A., Furuya T., Tangoku A., Oka M., and Sasaki K. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH Mod. Pathol. 17 2004 617 622
83. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., and Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade J. Biol. 2 2003 28
84. Hemmings B.A. Akt signaling: Linking membrane events to life and death decisions Science 275 1997 628 630
85. Hidalgo M. New target, new drug, old paradigm J. Clin. Oncol. 22 2004 2270 2272
86. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., and Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice Nat. Genet. 25 2000 55 57
87. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., Mizuno K., Hasegawa G., Kishimoto H., Iizuka M., Naito M., Enomoto K., Watanabe S., Mak T.W., and Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas J. Clin. Invest. 113 2004 1774 1783
88. Horiguchi A., Oya M., Uchida A., Marumo K., and Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma J. Urol. 169 2003 710 713
89. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaffe R.B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res. 62 2002 1087 1092
90. Huang S., Shu L., Easton J., Harwood F.C., Germain G.S., Ichijo H., and Houghton P.J. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity J. Biol. Chem. 279 2004 36490 36496
91. Huang X., Begley M., Morgenstern K.A., Gu Y., Rose P., Zhao H.L., and Zhu X.T. Crystal structure of an inactive Akt2 kinase domain Structure 11 2003 21 30
92. Hutchinson J., Jin J., Cardiff R.D., Woodgett J.R., and Muller W.J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression Mol. Cell. Biol. 21 2001 2203 2212
93. Hutchinson J.N., Jin J., Cardiff R.D., Woodgett J.R., and Muller W.J. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion Cancer Res. 64 2004 3171 3178
94. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat. Cell. Biol. 4 2002 648 657
95. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
96. Jetzt A., Howe J.A., Horn M.T., Maxwell E., Yin Z., Johnson D., and Kumar C.C. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice Cancer Res. 63 2003 6697 6706
97. Jiang Z.Y., Zhou Q.L., Coleman K.A., Chouinard M., Boese Q., and Czech M.P. Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing Proc. Natl. Acad. Sci. USA 100 2003 7569 7574
98. Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., and Hemmings B.A. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily Proc. Natl. Acad. Sci. USA 88 1991 4171 4175
99. Jucker M., Sudel K., Horn S., Sickel M., Wegner W., Fiedler W., and Feldman R.A. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO) Leukemia 16 2002 894 901
100. Kang S.S., Kwon T., Kwon D.Y., and Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit J. Biol. Chem. 274 1999 13085 13090
101. Katome T., Obata T., Matsushima R., Masuyama N., Cantley L.C., Gotoh Y., Kishi K., Shiota H., and Ebina Y. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions J. Biol. Chem. 278 2003 28312 32823
102. Kenerson H.L., Aicher L.D., True L.D., and Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors Cancer Res. 62 2002 5645 5650
103. Kim D.H., and Sabatini D.M. Raptor and mTOR: Subunits of a nutrient-sensitive complex Curr. Top. Microbiol. Immunol. 279 2004 259 270
104. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., and Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414
105. Knobbe C.B., and Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3 ′-kinase/ protein kinase B (Akt) signal transduction pathway in glioblastomas Brain Pathol. 13 2003 507 518
106. Knuutila S., Bjorkqvist A.M., Autio K., Tarkkanen M., Wolf M., Monni O., Szymanska J., Larramendy M.L., Tapper J., Pere H., El-Rifai W., Hemmer S., Wasenius V.M., Vidgren V., and Zhu Y. DNA copy number amplifications in human neoplasms: Review of comparative genomic hybridization studies Am. J. Pathol. 152 1998 1107 1123
107. Kohn A.D., Summers S.A., Birnbaum M.J., and Roth R.A. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation J. Biol. Chem. 271 1996 31372 31378
108. Komander D., Kular G.S., Bain J., Elliott M., Alessi D.R., and Van Aalten D.M. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition Biochem. J. 375 2003 255 262
109. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., and Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation Mol. Cancer Ther. 2 2003 1093 1103
110. Kops G.J., Medema R.H., Glassford J., Essers M.A., Dijkers P.F., Coffer P.J., Lam E.W., and Burgering B.M. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors Mol. Cell. Biol. 22 2002 2025 2036
111. Kozikowski A.P., Sun H., Brognard J., and Dennis P.A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt J. Am. Chem. Soc. 125 2003 1144 1145
112. Kulik G., Klippel A., and Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt Mol. Cell Biol. 3 1997 1595 1606
113. Kumar C.C., Diao R., Yin Z., Liu Y., Samatar A.A., Madison V., and Xiao L. Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling Biochim. Biophys. Acta 1526 2001 257 268
114. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., and Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am. J. Pathol. 158 2001 2097 2106
115. Kwiatkowski D.J. Tuberous sclerosis: From tubers to mTOR Ann. Hum. Genet. 67 2003 87 96
116. Kwon C.H., Zhu X., Zhang J., Knoop L.L., Tharp R., Smeyne R.J., Eberhart C.G., Burger P.C., and Baker S.J. Pten regulates neuronal soma size: A mouse model of Lhermitte-Duclos disease Nat. Genet. 29 2001 404 411
117. Kwon C.H., Zhu X., Zhang J., and Baker S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo Proc. Natl. Acad. Sci. USA 100 2003 12923 12928
118. Kyriakis J.M. At the crossroads: AMP-activated kinase and the LKB1 tumor suppressor link cell proliferation to metabolic regulation J. Biol. 2 2003 26
119. Lawlor M.A., Mora A., Ashby P.R., Williams M.R., Murray-Tait V., Malone L., Prescott A.R., Lucocq J.M., and Alessi D.R. Essential role of PDK1 in regulating cell size and development in mice EMBO J. 21 2002 3728 3738
120. Lee S.H., Kim H.S., Park W.S., Kim S.Y., Lee K.Y., Kim S.H., Lee J.Y., and Yoo N.J. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study APMIS 110 2002 587 592
121. Li G., Robinson G.W., Lesche R., Martinez-Diaz H., Jiang Z., Rozengurt N., Wagner K.U., Wu D.C., Lane T.F., Liu X., Hennighausen L., and Wu H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland Development 129 2002 4159 4170
122. Li J., Simpson L., Takahashi M., Miliaresis C., Myers M.P., Tonks N., and Parsons R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene Cancer Res. 58 1998 5667 5672
123. Li Y., Corradetti M.N., Inoki K., and Guan K.L. TSC2: Filling the GAP in the mTOR signaling pathway Trends Biochem. Sci. 29 2004 32 38
124. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., and Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome Nat. Genet. 16 1997 64 67
125. Liu A.X., Testa J.R., Hamilton T.C., Jove R., Nicosia S.V., and Cheng J.Q. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells Cancer Res. 58 1998 2973 2977
126. Long X., Muller F., and Avruch J. TOR action in mammalian cells and in Caenorhabditis elegans Curr. Top. Microbiol. Immunol. 279 2004 115 138
127. Lu Y., Lin Y.Z, LaPushin R., Cuevas B., Fang X., Yu S.X., Davies M.A., Khan H., Furui T., Mao M., Zinner R., Hung M.C., Steck P., Siminovitch K., and Mills G.B. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells Oncogene 18 1999 7034 7045
128. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise Cancer Cell 4 2003 257 262
129. Maira S.M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., and Hemmings B.A. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane Science 294 2001 374 380
130. Majumder P.K., Yeh J.J., George D.J., Febbo P.G., Kum J., Xue Q., Bikoff R., Ma H., Kantoff P.W., Golub T.R., Loda M., and Sellers W.R. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model Proc. Natl. Acad. Sci. USA 100 2003 7841 7846
131. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., and Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat. Med. 10 2004 594 601
132. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., and Kreisberg J.I. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer Clin. Cancer Res. 8 2002 1168 1171
133. Malstrom S., Tili E., Kappes D., Ceci J.D., and Tsichlis P.N. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus Proc. Natl. Acad. Sci. USA 98 2001 14967 14972
134. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., and Sonenberg N. eIF4E-from translation to transformation Oncogene 23 2004 3172 3179
135. Manning B.D., and Cantley L.C. Rheb fills a GAP between TSC and TOR Trends Biochem. Sci. 28 2003 573 576
136. Marino S., Krimpenfort P., Leung C., van der Korput H.A., Trapman J., Camenisch I., Berns A., and Brandner S. PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum Development 129 2002 3513 3522
137. Marsh D.J., Dahia P.L., Zheng Z., Liaw D., Parsons R., Gorlin R.J., and Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome Nat. Genet. 16 1997 333 334
138. Martelli A.M., Tazzari P.L., Tabellini G., Bortul R., Billi A.M., Manzoli L., Ruggeri A., Conte R., and Cocco L. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells Leukemia 17 2003 1794 1805
139. Martin K.A., and Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways Adv. Cancer Res. 86 2002 1 39
140. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinaseAkt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus Proc. Natl. Acad. Sci. USA 98 2001 11598 11603
141. Mellinghoff I.K., and Sawyers C.L. TORward AKTually useful mouse models Nat. Med. 10 2004 579 580
142. Mende I., Malstrom S., Tsichlis P.N., Vogt P.K., and Aoki M. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3 Oncogene 20 2001 4419 4423
143. Min Y.H., Eom J.I., Cheong J.W., Maeng H.O., Kim J.Y., Jeung H.K., Lee S.T., Lee M.H., Hahn J.S., and Ko Y.W. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable Leukemia 17 2003 995 997
144. Mitsiades C.S., Mitsiades N., and Koutsilieris M. The Akt pathway: Molecular targets for anti-cancer drug development Curr. Cancer Drug Targets 4 2004 235 256
145. Miwa W., Yasuda J., Murakami Y., Yashima K., Sugano K., Sekine T., Kono A., Egawa S., Yamaguchi K., Hayashizaki Y., and Sekiya T. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer Biochem. Biophys. Res. Commun. 225 1996 968 974
146. Miyakawa M., Tsushima T., Murakami H., Wakai K., Isozaki O., and Takano K. Increased expression of phosphorylated p70S6 kinase and akt in papillary thyroid cancer tissues Endocr. J. 50 2003 77 83
147. Mohi M.G., Boulton C., Gu T.L., Sternberg D.W., Neuberg D., Griffin J.D., Gilliland D.G., and Neel B.G. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs Proc. Natl. Acad. Sci. USA 101 2004 3130 3135
148. Muise-Helmericks R.C., Grimes H.L., Bellacosa A., Malstrom S.E., Tsichlis P.N., and Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway J. Biol. Chem. 273 1998 29864 29872
149. Mukohara T., Kudoh S., Matsuura K., Yamauchi S., Kimura T., Yoshimura N., Kanazawa H., Hirata K., Inoue K., Wanibuchi H., Fukushima S., and Yoshikawa J. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC Anticancer Res. 24 2004 11 17
150. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., and Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function Proc. Natl. Acad. Sci. USA 95 1998 13513 13518
151. Nakashio A., Fujita N., Rokudai S., Sato S., and Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis Cancer Res. 60 2000 5303 5309
152. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., and Roth R.A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines J. Biol. Chem. 274 1999 21528 21532
153. Nam S.Y., Lee H.S., Jung G.A., Choi J., Cho S.J., Kim M.K., Kim W.H., and Lee B.L. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis APMIS 111 2003 1105 1113
154. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., and Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. USA 98 2001 10314 10319
155. Ono H., Shimano H., Katagiri H., Yahagi N., Sakoda H., Onishi Y., Anai M., Ogihara T., Fujishiro M., Viana A.Y., Fukushima Y., Abe M., Shojima N., Kikuchi M., Yamada N., Oka Y., and Asano T. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement Diabetes 52 2003 2905 2913
156. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., and Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system Cancer Cell 1 2002 53 62
157. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M., and Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis Anticancer Res. 20 2000 407 416
158. Pearl L.H., and Barford D. Regulation of protein kinases in insulin, growth factor and Wnt signalling Curr. Opin. Struct. Biol. 12 2002 761 767
159. Peng X.D., Xu P.Z., Chen M.L., Hahn-Windgassen A., Skeen J., Jacobs J., Sundararajan D., Chen W.S., Crawford S.E., Coleman K.G., and Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2 Genes Dev. 17 2003 1352 1365
160. Perez-Tenorio G., and Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br. J. Cancer 86 2002 540 545
161. Philp A.J., Campbell I.G., Leet C., Vincan E., Rockman S.P., Whitehead R.H., Thomas R.J., and Phillips W.A. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors Cancer Res. 61 2001 7426 7429
162. Plas D.R., and Thompson C.B. Cell metabolism in the regulation of programmed cell death Trends Endocrinol. Metab. 13 2002 75 78
163. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proc. Natl. Acad. Sci. USA 96 1999 1563 1568
164. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., and Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc. Natl. Acad. Sci. USA 98 2001 10320 10325
165. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2 Nat. Cell Biol. 4 2002 658 665
166. Proud C.G. Role of mTOR signalling in the control of translation initiation and elongation by nutrients Curr. Top. Microbiol. Immunol. 279 2004 215 244
167. Rathmell J.C., Elstrom R.L., Cinalli R.M., and Thompson C.B. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma Eur. J. Immunol. 33 2003 2223 2232
168. Reith A.D., Ellis C., Lyman S.D., Anderson D.M., Williams D.E., Bernstein A., and Pawson T. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase EMBO J. 10 1991 2451 2459
169. Ringel M.D., Hayre N., Saito J., Saunier B., Schuppert F., Burch H., Bernet V., Burman K.D., Kohn L.D., and Saji M. Overexpression and overactivation of Akt in thyroid carcinoma Cancer Res. 61 2001 6105 6111
170. Roy H.K., Olusola B.F., Clemens D.L., Karolski W.J., Ratashak A., Lynch H.T., and Smyrk T.C. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis Carcinogenesis 23 2002 201 205
171. Ruggeri B.A., Huang L., Wood M., Cheng J.Q., and Testa J.R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas Mol. Carc. 21 1998 81 86
172. Ruggero D., and Pandolfi P.P. Does the ribosome translate cancer? Nat. Rev. Cancer 3 2003 179 192
173. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., and Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis Nat. Med. 10 2004 484 486
174. Saito Y., Swanson X., Mhashilkar A.M., Oida Y., Schrock R., Branch C.D., Chada S., Zumstein L., and Ramesh R. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo Gene Ther. 10 2003 1961 1969
175. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
176. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway J. Clin. Oncol. 22 2004 2954 2963
177. Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., and Abraham R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin Cancer Res. 58 1998 4375 4382
178. Sato S., Fujita N., and Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) Oncogene 11 2002 1727 1738
179. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 5 2003 343 348
180. Scheid M.P., and Woodgett J.R. Unravelling the activation mechanisms of protein kinase B/Akt FEBS Lett. 546 2003 108 112
181. Schlegel J., Piontek G., and Mennel H.D. Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo Anticancer Res. 22 2002 2837 2840
182. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., and Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer Br. J. Cancer 89 2003 2110 2115
183. Seki N., Takasu T., Mandai K., Nakata M., Saeki H., Heike Y., Takata I., Segawa Y., Hanafusa T., and Eguchi K. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung Clin. Cancer Res. 8 2002 3046 3053
184. Semba S., Moriya T., Kimura W., and Yamakawa M. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas Pancreas 26 2003 250 257
185. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., and Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 6 2004 91 99
186. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., and Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. USA 101 2004 3329 3335
187. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer Nat. Genet. 21 1999 99 102
188. She Q.B., Solit D., Basso A., and Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling Clin. Cancer Res. 12 2003 4340 4346
189. Shi W., Zhang X., Pintilie M., Ma N., Miller N., Banerjee D., Tsao M.S., Mak T., Fyles A., and Liu F.F. Dysregulated PTEN-PKB and negative receptor status in human breast cancer Int. J. Cancer 104 2003 195 203
190. Simpson L., and Parsons R. PTEN: Life as a tumor suppressor Exp. Cell Res. 264 2001 29 41
191. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., Wasik M.A., Tsichlis P.N., and Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway EMBO J. 16 1997 6151 6161
192. Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione A., Majewski M., Xue L., Morris S.W., Wasik M.A., and Skorski T. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis Cancer Res. 61 2001 2194 2199
193. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites Development 124 1997 2691 2700
194. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma Proc. Natl. Acad. Sci. USA 84 1987 5034 5037
195. Staal S.P., and Hartley J.W. Thymic lymphoma induction by the AKT8 murine retrovirus J. Exp. Med. 167 1988 1259 1264
196. Staal S.P., Hartley J.W., and Rowe W.P. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma Proc. Natl. Acad. Sci. USA 74 1977 3065 3067
197. Staal S.P., Huebner K., Croce C.M., Parsa N.Z., and Testa J.R. The AKT1 proto-oncogene maps to human chromosome 14, band q32 Genomics 2 1988 96 98
198. Stal O., Perez-Tenorio G., Akerberg L., Olsson B., Nordenskjold B., Skoog L., and Rutqvist L.E. Akt kinases in breast cancer and the results of adjuvant therapy Breast Cancer Res. 5 2003 R37 R44
199. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., and Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 95 1998 29 39
200. Staveley B.E., Ruel L., Jin J., Stambolic V., Mastronardi F.G., Heitzler P., Woodgett J.R., and Manoukian A.S. Genetic analysis of protein kinase B (AKT) in Drosophila Curr. Biol. 8 1998 599 602
201. Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., Ma X.L., Shelley S.A., Jove R., Tsichlis P.N., Nicosia S.V., and Cheng J.Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am. J. Pathol. 159 2001 431 437
202. Sun S., and Steinberg B.M. PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells J. Gen. Virol. 83 2002 1651 1658
203. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., and Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice Curr. Biol. 8 1998 1169 1178
204. Suzuki A., Yamaguchi M.T., Ohteki T., Sasaki T., Kaisho T., Kimura Y., Yoshida R., Wakeham A., Higuchi T., Fukumoto M., Tsubata T., Ohashi P.S., Koyasu S., Penninger J.M., Nakano T., and Mak T.W. T cell-specific loss of Pten leads to defects in central and peripheral tolerance Immunity 14 2001 523 534
205. Tanno S., Tanno S., Mitsuuchi Y., Altomare D.A., Xiao G.H., and Testa J.R. AKT activation up-regulates insulin-like growth factor-I receptor expression and promotes invasiveness of human pancreatic cancer cells Cancer Res. 61 2001 589 593
206. Tanno S., Yanagawa N., Habiro A., Koizumi K., Nakano Y., Osanai M., Mizukami Y., Okumura T., Testa J.R., and Kohgo Y. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance Cancer Res. 64 2004 3486 3490
207. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer Endocr. Relat. Cancer 10 2003 203 208
208. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis Proc. Natl. Acad. Sci. USA 98 2001 10983 10985
209. Thant A.A., Nawa A., Kikkawa F., Ichigotani Y., Zhang Y., Sein T.T., Amin A.R., and Hamaguchi M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells Clin. Exp. Metastasis 18 2000 423 428
210. Thomas C., Deak M., Alessi D., and van Aalten D. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate Curr. Biol. 12 2002 1256
211. Thompson F.H., Nelson M.A., Trent J.M., Guan X.Y., Liu Y., Yang J.M., Emerson J., Adair L., Wymer J., Balfour C., Massey K., Weinstein R., Alberts D.S., and Taetle R. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies Cancer Genet. Cytogenet. 87 1996 55 62
212. Trencia A., Perfetti A., Cassese A., Vigliotta G., Miele C., Oriente F., Santopietro S., Giacco F., Condorelli G., Formisano P., and Beguinot F. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action Mol. Cell. Biol. 23 2003 4511 4521
213. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Dyke T.V., Cordon-Cardo C., and Pandolfi P. Pten dose dictates cancer progression in the prostate PLoS Biol. 1 2003 E59
214. Tsao A.S., McDonnell T., Lam S., Putnam J.B., Bekele N., Hong W.K., and Kurie J.M. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: Implications for lung cancer prevention studies Cancer Epidemiol. Biomarkers Prev. 12 2003 660 664
215. Tuttle R.L., Gill N.S., Pugh W., Lee J.P., Koeberlein B., Furth E.E., Polonsky K.S., Naji A., and Birnbaum M.J. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha Nat. Med. 7 2001 1133 1137
216. Tybulewicz V.L., Crawford C.E., Jackson P.K., Bronson R.T., and Mulligan R.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene Cell 65 1991 1153 1163
217. Uhrbom L., Dai C., Celestino J.C., Rosenblum M.K., Fuller G.N., and Holland E.C. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt Cancer Res. 62 2002 5551 5558
218. Vanhaesebroeck B., and Alessi D.R. The PI3K-PDK1 connection: More than just a road to PKB Biochem. J. 346 2000 561 576
219. Vasko V., Saji M., Hardy E., Kruhlak M., Larin A., Savchenko V., Miyakawa M., Isozaki O., Murakami H., Tsushima T., Burman K.D., De Micco C., and Ringel M.D. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer J. Med. Genet. 41 2004 161 170
220. Verdu J., Buratovich M.A., Wilder E.L., and Birnbaum M.J. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB Nat. Cell Biol. 1 1999 500 506
221. Vezina C., Kudelski A., and Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J. Antibiot. (Tokyo) 28 1975 721 726
222. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer Nat. Med. 8 2002 1136 1144
223. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
224. Waldmann V., and Wacker J. Mutations of the PH domain of protein kinase B (PKB/AKT) are absent in human epidermal skin tumors Dermatology 203 2001 284 288
225. Waldmann V., Wacker J., and Deichmann M. Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma Arch. Dermatol. Res. 293 2001 368 372
226. Waldmann V., Wacker J., and Deichmann M. Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma Melanoma Res. 12 2002 45 50
227. Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., and Alessi D.R. Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: Comparison with protein kinase B alpha Biochem. J. 331 1998 299 308
228. Wang S., Rosenwald I.B., Hutzler M.J., Pihan G.A., Savas L., Chen J.J., and Woda B.A. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas Am. J. Pathol. 155 1999 247 255
229. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., and Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209 221
230. Warburg O. On the origin of cancer cells Science 123 1956 309 314
231. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 2004 332 337
232. Whang Y.E., Yuan X.J., Liu Y., Majumder S., and Lewis T.D. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor Vitam. Horm. 67 2004 409 426
233. Whiteman E.L., Cho H., and Birnbaum M.J. Role of Akt/protein kinase B in metabolism Trends Endocrinol. Metab. 13 2002 444 451
234. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., and Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade Curr. Biol. 13 2003 2004 2008
235. Wu H., Goel V., and Haluska F.G. PTEN signaling pathways in melanoma Oncogene 22 2003 3113 3122
236. Wu X., Senechal K., Neshat M.S., Whang Y.E., and Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway Proc. Natl. Acad. Sci. USA 95 1998 15587 15591
237. Xie Z., Zeng X., Waldman T., and Glazer R.I. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1 Cancer Res. 17 2003 5370 5375
238. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of of the tyrosine kinase c-Src Nature 385 1999 595 602
239. Xu X., Sakon M., Nagano H., Hiraoka N., Yamamoto H., Hayashi N., Dono K., Nakamori S., Umeshita K., Ito Y., Matsuura N., and Monden M. Akt2 expression correlates with prognosis of human hepatocellular carcinoma Oncol. Rep. 11 2004 25 32
240. Yang J., Cron P., Good V.M., Thompson V., Hemmings B.A., and Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP Nat. Struct. Biol. 9 2002 940 944
241. Yang J., Cron P., Thompson V., Good V.M., Hess D., Hemmings B.A., and Barford D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation Mol. Cell 9 2002 1227 1240
242. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., Sebti S.M., and Cheng J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt Cancer Res. 64 2004 4394 4399
243. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., Coppola D., Nicosia S.V., and Cheng J.Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2000 2324 2330
244. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., and Kwiatkowski D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR J. Clin. Invest. 112 2003 1223 1233
245. Zhou B.P., and Hung M.C. Dysregulation of cellular signaling by HER2/neu in breast cancer Semin. Oncol. 30 2003 38 48
246. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells Nat. Cell Biol. 3 2001 245 252